γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

Summary

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Natasja L. de Vries, Joris van de Haar, Vivien Veninga, Myriam Chalabi, Marieke E. Ijsselsteijn, Manon van der Ploeg, Jitske van den Bulk, Dina Ruano, Jose G. van den Berg, John B. Haanen, Laurien J. Zeverijn, Birgit S. Geurts, Gijs F. de Wit, Thomas W. Battaglia, Hans Gelderblom, Henk M. W. Verheul, Ton N. Schumacher, Lodewyk F. A. Wessels, Frits Koning, Noel F. C. C. de Miranda, Emile E. Voest

Journal title: Nature

Journal number: 613

Journal publisher: Nature Publishing Group

Published year: 2023

Published pages: 743-750

DOI identifier: 10.1038/s41586-022-05593-1

ISSN: 0028-0836